HONG KONG, Jan. 16, 2026 — Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a January 12, 2026 notification letter (the “Notification Letter”) from Nasdaq’s Listing Qualifications Department. The letter indicated that the closing bid price of the Company’s Class A ordinary shares—each with a par value of US$0.001—was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026. As a result, the Company is currently not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
The notification letter has no immediate impact on the listing of the Company’s Class A ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker symbol “HKPD.”
Under Listing Rule 5810(c)(3)(A), the Company has a 180-calendar-day compliance period—until July 13, 2026—to regain compliance with the minimum bid price rule. If at any point during this 180-day window the closing bid price per share of the Company’s Class A ordinary shares is US$1.00 or above for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed.
If the Company does not regain compliance with the minimum bid price requirement by July 13, 2026, it may be eligible for an additional 180-calendar-day grace period to meet the standard. To qualify, the Company must satisfy the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market—with the exception of the bid price requirement—and provide written notice of its intention to remedy the deficiency during the second compliance period, including via a reverse share split if necessary. Should the Company choose to implement a reverse share split, it must complete the split no later than 10 business days prior to July 13, 2026 or the expiration of the second compliance period (if granted).
This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of receiving a deficiency notification. The Company is currently exploring various options to regain such compliance. The notification letter has no effect on the listing of the Company’s Class A ordinary shares at this time, which will continue to trade uninterrupted on Nasdaq under the ticker “HKPD.”
About Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd (formerly Hong Kong Pharma Digital Technology Holdings Limited) offers two main service categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.
Through its partnerships with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China.
Joint Cross Border’s comprehensive services include pre-consultation, product information review, sourcing overseas OTC pharmaceutical products, registering products with the Hong Kong Department of Health, obtaining import and export permits, product storage, packaging, and arranging logistics and end-to-end delivery for customers.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. All forward-looking statements—expressed or implied—in this release are based solely on information currently available to us and speak only as of the date of issuance. Investors can identify many (but not all) of these statements using terms like “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions in this release. Except as required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including (but not limited to) market condition uncertainties and other factors discussed in our SEC filings. While the Company believes the expectations in these forward-looking statements are reasonable, it cannot guarantee they will be correct. The Company cautions investors that actual results may differ materially from anticipated results and encourages them to review other factors affecting future results in the Company’s SEC filings. Additional factors are discussed in the Company’s SEC filings, available for review at [link]. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect post-release events or circumstances.
For investor and media inquiries please contact:
Cellyan Biotechnology Co., Ltd
Media Contact:
Investor Relations:
